PHILADELPHIA — Continuous intracerebroventricular administration of an anaerobic dopamine formulation (A-dopamine) appears safe in patients with Parkinson’s disease (PD) and may avoid complications associated with levodopa, results from a first in-human trial suggest. A-dopamine induced a dose-dependent improvement in motor symptoms in refractory patients with severe levodopa complications and had a “really great” safety profile, said study investigator...
